×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
China Medical System Holdings Full Year 2023 Earnings: Misses Expectations
Simply Wall Street
China Medical System Holdings ( HKG:867 ) Full Year 2023 Results Key Financial Results Revenue: CN¥8.01b (down 12% from...
3 weeks ago
Spasticity Market Likely to Exhibit Substantial Growth by 2032, Predicts DelveInsight | Key Pharma Companies - Saol ...
PR Newswire
PRNewswire/ -- DelveInsight's Spasticity Market Insights report includes a comprehensive understanding of current treatment practices,...
5 months ago
NeoImmuneTech bags orphan drug tag for IL-7 acute radiation syndrome treatment
Pharmaceutical Technology
NeoImmuneTech is developing NT-17, an IL-7 treatment, to promote rapid T-cell recovery in patients with acute radiation syndrome.
5 months ago
FDA Filings Roundup
Contract Pharma
Basilea's antibiotic ZEVTERA approved for three indications, Vanda Pharmaceuticals' Fanapt approved for acute Bipolar I Disorder.
1 month ago
International consortium identifies biomarkers for cardiovascular disease in diabetes - PharmaTimes
PharmaTimes
Type 2 diabetes is estimated to affect 462 million people worldwide. An international academic consortium led by Johns Hopkins University,...
3 months ago
FDA names NeoImmuneTech’s ‘NT-I7’ as orphan drug for pancreatic cancer
KBR
NeoImmuneTech said Thursday that NT-I7 (efineptakin alfa) has received orphan drug designation (ODD) from the U.S. Food and Drug...
3 months ago
Clarity Pharma says its prostate cancer treatment has achieved ‘complete response’
NT News
Clarity Pharma (ASX:CU6) jumped 7 per cent on Tuesday morning after revealing that the first prostate cancer patient t dosed with two cycles...
1 week ago
NeoImmuneTech Gets Orphan Status For Pancreatic Cancer Drug
Contract Pharma
Clinical trials demonstrate potential to amplify T cells, boost the immune system, and enhance the anti-tumor response.
4 months ago
NT PHARMA(01011.HK) Interim Loss Narrows to RMB5.612M
AASTOCKS.com
NT PHARMA (01011.HK) announced interim result ended June 2023. The turnover declined 31.4% year on year to RMB82.609 million.
8 months ago
Is Lotus Pharmaceutical Co., Ltd.'s (TWSE:1795) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Simply Wall Street
Most readers would already be aware that Lotus Pharmaceutical's (TWSE:1795) stock increased significantly by 13% over...
2 months ago